This page was created for families, caregivers, and advocates whose children have been diagnosed with a CUX2-related condition, including Developmental and Epileptic Encephalopathy 67 (DEE67). Our goal is to provide a single, centralized location where you can find and understand the published scientific research on CUX2 without needing a medical or scientific background to navigate it.
Finding and reading medical research can be overwhelming. Journal articles are written for scientists and clinicians, often behind paywalls, and filled with technical language that is difficult to interpret without specialized training. This library exists to change that. Each article listed here includes a plain-language summary written to help you understand what the researchers studied, what they found, and why it matters for your family.
The plain-language summaries on this page were generated with the assistance of Claude, an artificial intelligence tool developed by Anthropic. Each summary was produced by providing Claude with the full text or publicly available content of the corresponding research article and asking it to explain the findings in clear, accessible language suitable for parents and non-medical readers.
We chose to use AI assistance because the volume and complexity of medical research presents a real barrier for families navigating a rare diagnosis. These summaries are intended to lower that barrier and help you engage more confidently with the science.
Please read the following carefully before using any information on this page.
The summaries provided here are generated by an artificial intelligence system and are intended for general informational and educational purposes only. They are not a substitute for professional medical advice, diagnosis, or treatment.
AI systems, including Claude, can make errors. Summaries may occasionally misrepresent, oversimplify, or omit details from the original research. The original published articles are the authoritative source of scientific information, and we encourage you to read them directly or share them with your child's medical team whenever possible. Links to each original article are provided alongside every summary on this page.
Nothing on this page should be used to make medical decisions for your child. Every child with a CUX2-related condition is different, and what applies to one patient may not apply to another. Always consult your child's neurologist, geneticist, or other qualified healthcare professionals before making any changes to treatment, medication, or care.
This page will be updated as new research is published. The science of CUX2 and DEE67 is still developing, and our understanding of this condition continues to evolve. If you are aware of a published article that should be included here and is not, please contact the CUX2 Foundation so we can review and add it.
The CUX2 Foundation does not endorse any specific treatment, medication, or therapeutic approach referenced in the research articles listed on this page. The inclusion of a study in this library does not imply that its findings have been validated, replicated, or approved for clinical use.
DNA Damage Burden Causes Selective CUX2 Neuron Loss in Neuroinflammation
Publication Date: April 1, 2026
Primary Researchers: Laura Morcom, Wenlong Xia, Zhaoyang Xu, and colleagues including David H. Rowitch, Stephen P. J. Fancy, Gabriel Balmus, Lucas Schirmer, Brian Popko, and Daniel Geschwind, from institutions including the University of Cambridge, UC San Francisco, Northwestern University, Heidelberg University, and others (Nature)
AI Summary: This paper investigates why CUX2-expressing excitatory neurons in cortical layers 2 and 3 (L2/3) are selectively lost during neuroinflammatory conditions, using multiple sclerosis (MS) as the primary disease model. Researchers had previously documented that these neurons degenerate disproportionately in MS but did not know why. This study identifies the underlying mechanism: L2/3 neurons in MS carry a significantly elevated burden of DNA damage, and CUX2 itself plays an essential role in helping those neurons repair that damage. When CUX2 function is absent or impaired, the DNA repair system in these neurons degrades, and the neurons die.
The researchers confirmed these findings across human MS brain tissue and multiple mouse models of demyelination and neuroinflammation. They also identified interferon-gamma, a cytokine released during immune activity, as a key upstream driver of the process. Interferon-gamma increases reactive oxygen species in neurons, which causes oxidative DNA damage. In mice engineered to express interferon-gamma chronically in the brain, L2/3 neurons were selectively lost even without gross demyelination, confirming that inflammation alone is sufficient to cause this damage pattern. A companion transcription factor, ATF4, was found to work alongside CUX2 in this repair process, and mice lacking both showed accelerated and more severe neuron loss.
For the CUX2 community, this paper provides the first in vivo demonstration that CUX2 functions as a DNA damage repair factor in cortical neurons, extending prior in vitro evidence and establishing the mechanism in a disease context. The paper also explicitly notes that CUX2 dysfunction in mice and humans is associated with seizure susceptibility, citing prior CUX2-relevant literature, and suggests that accumulated DNA damage from impaired CUX2 repair function may partially explain that connection.
Expansion of Outer Cortical CUX2 Neurons Requires Adaptations for DNA Repair
Publication Date: April 1, 2026
Primary Researchers: Wenlong Xia, Laura Morcom, Zhaoyang Xu, and colleagues including David H. Rowitch, Stephen P. J. Fancy, Brian Popko, Daniel H. Geschwind, and Ben Emery, from institutions including UC San Francisco, the University of Cambridge, and Oregon Health and Science University (Nature)
AI Summary: This companion paper to the Morcom et al. study above addresses an earlier question in the same biological story: how do CUX2-expressing neurons in cortical layers 2 and 3 develop in the first place, and why are they so vulnerable? The paper focuses on embryonic brain development and identifies ATF4 as a transcription factor that is essential specifically for the survival of CUX2+ neuronal progenitors during the period of rapid cell division that produces the upper cortical layers.
The researchers found that when ATF4 is removed from all cortical progenitor cells in mice, the only neurons eliminated are CUX2+ upper-layer excitatory neurons. Deeper-layer neurons, interneurons, and other cell types are unaffected, including calbindin-expressing interneurons that predominantly occupy L2/3. This happens because CUX2+ progenitors are the last to emerge from the proliferative zone during brain development, meaning they are exposed to oxidative stress and the resulting DNA damage for a longer cumulative period than progenitors destined for deeper layers. Without ATF4, these progenitors accumulate catastrophic DNA damage and die through a p53-dependent apoptosis pathway. ATF4 was shown to directly activate three key DNA repair genes (CIRBP, UBA52, and EBF1), and CIRBP in particular was found to be required for normal phosphorylation of ATM at Ser1981, a modification necessary for ATM's stable retention at DNA break sites and its ability to initiate downstream double-strand break repair.
For the CUX2 community, this paper reframes CUX2 neurons as a cell population that requires extraordinary DNA repair capacity from their earliest developmental origins, not just during inflammation or disease. It establishes that the same vulnerability documented in MS and neuroinflammation has a developmental basis rooted in the biology of how these neurons are made. The paper also explicitly situates CUX2+ L2/3 neurons within a broader landscape of disease vulnerability, noting documented losses of these neurons in MS, traumatic brain injury in young athletes, Alzheimer's disease, frontotemporal dementia, epilepsy, schizophrenia, and autism.
A Novel Frameshift CUX2 Variant in a Patient with Epilepsy and Global Developmental Delay: Phenotypic and Genotypic Expansion
Publication Date: September 2025 (preprint, not yet formally published in a journal)
Primary Researchers: Ferruccio Romano, Mohammad Sadegh Shams Nosrati, Francesca Madia, Marzia Ognibene, Monica Traverso, Marta Breda, Alireza Dostmohammadi, Marcello Scala, Federico Zara, Maria Margherita Mancardi, Valeria Capra
AI Summary: This paper describes a single child diagnosed with epilepsy and significant developmental delay who was found to have a CUX2 mutation. What made this case unusual is the type of mutation involved. Every previously reported DEE67 patient had what scientists call a missense mutation, which is like a single wrong letter in a very long sentence of genetic instructions. This child had a frameshift mutation, which is a more severe type of error where letters are deleted from the sentence, causing everything that follows to be read incorrectly. This kind of mistake typically prevents the CUX2 protein from being made at all.
The significance of this finding is that it proves DEE67 is not limited to one specific type of genetic error. More types of CUX2 damage can lead to the same condition than was previously understood. This is important for families and doctors because it means genetic testing for DEE67 needs to look beyond just the most commonly reported mutation. The paper is a preprint, which means it has been shared with the scientific community for review but has not yet completed the full journal publication process.
URL: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5517855
CUX1-Related Neurodevelopmental Disorder: Deep Insights into Phenotype-Genotype Spectrum and Underlying Pathology
Publication Date: August 30, 2023
Primary Researchers: Henrike Oppermann and an international team of researchers (European Journal of Human Genetics)
AI Summary: This paper is primarily about CUX1, which is a gene that works in a very similar way to CUX2 and sits in the same gene family. Researchers followed 34 patients who had mutations in CUX1 and documented their symptoms, severity, and developmental outcomes in detail. The main findings were that CUX1 patients experienced delays in speech and physical development and mild to moderate intellectual disability. Some patients showed improvement over time. Mouse experiments confirmed that having only one working copy of CUX1 rather than two raised the risk of seizures, mirroring what has been found with CUX2.
For CUX2 families, this paper matters because the two genes are closely related and the biology overlaps significantly. The paper directly references CUX2 research and notes that CUX2 mutations tend to cause a more severe condition than CUX1. Reading about CUX1 outcomes can help families understand the range of possibilities within this gene family and gives researchers a comparison point for understanding what is specific to CUX2 and what is shared across related conditions.
Novel Variant Expands the Clinical Spectrum of CUX2-Associated Developmental and Epileptic Encephalopathies
Publication Date: June 14, 2022
Primary Researchers: Fang Zhang, Fang Li, Feng Chen, Jing Huang, Qun Luo, Xianhao Du, Jiong Zhou, Wei Gu, Kelin Xu (Frontiers in Genetics)
AI Summary: This paper reports the case of a 5.5-year-old boy in China who was diagnosed with DEE67. He had epilepsy, a developmental delay, and a speech delay. The genetic testing performed on him and both of his parents confirmed he had a CUX2 mutation that neither parent carried, meaning it arose spontaneously in him alone. The mutation found in this child was located in a different part of the CUX2 gene than the mutation seen in all previously known DEE67 patients. This was significant because it showed that DEE67 is not caused by only one specific genetic error, as had previously appeared to be the case.
An important finding in this case was that the child responded well to a seizure medication called levetiracetam and was seizure-free for six months at the time the paper was written. This was a more positive outcome than what most previously reported patients experienced, the majority of whom were resistant to multiple medications. While one case cannot draw broad conclusions, it raises the possibility that where a mutation sits within the CUX2 gene may influence both how severe the condition is and whether certain medications are more likely to help.
URL: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.808181/full
CUX2 Deficiency Causes Facilitation of Excitatory Synaptic Transmission onto Hippocampus and Increased Seizure Susceptibility to Kainate
Publication Date: May 17, 2022
Primary Researchers: Toshimitsu Suzuki, Tetsuya Tatsukawa, Genki Sudo, Caroline Delandre, Yun Jin Pai, Hiroyuki Miyamoto, Matthieu Raveau, and Kazuhiro Yamakawa (Scientific Reports, Nature Publishing Group)
AI Summary: This study asked a very specific question: when the CUX2 gene is broken, what exactly goes wrong inside the brain that causes seizures? To answer it, researchers studied 271 epilepsy patients in Japan and also conducted experiments in mice and fruit flies where CUX2 was deliberately removed or damaged. They found that brains without functioning CUX2 grew too many of a certain type of cell called excitatory neurons in a part of the brain called the entorhinal cortex. These extra cells sent abnormally strong electrical signals into the hippocampus, which is the brain region involved in memory and a known starting point for many seizures. This overload of signaling made the brain far more likely to have a seizure.
The fruit fly experiments supported these findings by showing that nerve cells without CUX2 grew shorter and less complex branches, meaning connections between brain cells were simpler and weaker than they should be. Together, these findings provide the most detailed explanation published to date of exactly how a broken CUX2 gene leads to seizures. This paper is considered foundational because it moves beyond simply identifying CUX2 as a problem and begins to show the step-by-step biological chain from genetic error to seizure activity.
A Recurrent De Novo CUX2 Missense Variant Associated with Intellectual Disability, Seizures, and Autism Spectrum Disorder
Publication Date: May 24, 2018
Primary Researchers: Maria Barington, Lotte Risom, Jakob Ek, Peter Uldall, Elsebet Ostergaard (European Journal of Human Genetics, Copenhagen University Hospital, Denmark)
Summary: This paper describes a single patient, a teenage girl in Denmark, who was diagnosed with epilepsy, moderate to severe intellectual disability, and infantile autism. Genetic testing confirmed she carried the same CUX2 mutation found in the other DEE67 patients, E590K, and that neither of her parents carried it, confirming it arose spontaneously. Her seizures included both generalized and muscle-jerking types. She had experienced developmental delays from infancy and her seizures began at 12 months of age.
The specific contribution of this paper was to formally document CUX2 as a cause of a condition that combines epilepsy, intellectual disability, and autism spectrum disorder together in the same patient. Prior to 2018, only two other patients with this mutation had been reported. Each new case helped establish that the link between this mutation and this cluster of symptoms was real and not coincidental. This paper also emphasized that CUX2 plays a fundamental role in how the human brain develops and functions, going well beyond seizure control alone.
The Epilepsy Phenotypic Spectrum Associated with a Recurrent CUX2 Variant
Publication Date: April 6, 2018
Primary Researchers: Nicolas Chatron, Rikke S. Moller, Nadia L. Champaigne, Amy L. Schneider, Alma Kuechler, Audrey Labalme, and an international research team including Gemma Carvill (Annals of Neurology)
AI Summary: This is the paper that formally established DEE67 as a recognized medical condition. Nine patients from multiple countries were identified, all carrying the exact same CUX2 mutation, known as E590K. The patients ranged in age from 6 months to 21 years at the time of the study. Seizures began on average at 6 months of age, though one patient did not begin having seizures until age 9. Seizure types varied widely and included muscle jerking seizures, absence seizures, and focal seizures. Seven of the nine patients were resistant to multiple seizure medications. Two had their seizures controlled with a medication called valproate. Six patients were classified as having a full developmental and epileptic encephalopathy, a medical term that means the epilepsy itself was damaging brain development.
Eight of the nine had significant cognitive impairment and six had features of autism.
This paper is the cornerstone of all DEE67 research. Before it was published, the link between CUX2 and this specific pattern of severe childhood epilepsy had not been formally established or named. Every subsequent DEE67 paper cites this one. For parents, it is the article that most directly describes the range of outcomes seen in children with the most common CUX2 mutation and gives the clearest picture of what the condition looks like across a group of patients rather than a single case.
Hotspots of Missense Mutation Identify Neurodevelopmental Disorder Genes and Functional Domains
Publication Date: June 19, 2017
Primary Researchers: Madeleine R. Geisheker, Gabriel Heymann, Tianyun Wang, Bradley P. Coe, Evan E. Eichler, and a large international research team (Nature Neuroscience)
AI Summary: This was a large-scale genetic screening study that analyzed nearly 18,000 patients with neurodevelopmental disorders, including autism, intellectual disability, and epilepsy, alongside healthy comparison groups. The researchers were looking for genes where spontaneous mutations appeared far more often in patients than would be expected by random chance. CUX2 was identified as one of 35 genes that showed this pattern clearly, meaning that mutations in CUX2 were clustering in patients with neurodevelopmental conditions in a way that strongly suggested the gene was causing the problems rather than just happening to be present.
This paper was published a year before the formal DEE67 papers and served as important early scientific evidence that CUX2 deserved much closer attention. It helped justify the targeted research that followed. For families, this paper represents the moment the broader scientific community flagged CUX2 as a high-priority gene in understanding why some children develop autism and intellectual disability. It also confirmed that the same mutation seen in DEE67 was appearing in patients diagnosed with autism spectrum disorder, reinforcing the connection between the two conditions.
De Novo Mutations in Epileptic Encephalopathies
Publication Date: August 11, 2013
Primary Researchers: Epi4K Consortium and Epilepsy Phenome/Genome Project, a large international collaboration led by Andrew S. Allen, Samuel F. Berkovic, David B. Goldstein, Heather C. Mefford, and Evan E. Eichler (Nature)
AI Summary: This was one of the most significant epilepsy genetics studies ever conducted at the time of publication. Researchers sequenced the genomes of 264 children with two of the most severe forms of childhood epilepsy, infantile spasms and Lennox-Gastaut syndrome, and compared their DNA to their parents to find mutations that appeared spontaneously rather than being inherited. The study confirmed that spontaneous genetic mutations are a major and previously underappreciated cause of the most severe childhood epilepsies. CUX2 was among the genes identified as carrying de novo mutations in this patient group.
This paper did not focus on CUX2 specifically, but it was part of the scientific movement that led researchers to recognize it as a cause of epileptic encephalopathy. It established that the genetic landscape of severe childhood epilepsy is far more complex and varied than previously understood, with hundreds of different genes potentially involved. For families, this paper represents a turning point in epilepsy science when the field began to understand that the most devastating childhood epilepsies often have a specific, identifiable genetic cause rather than being unexplained. It is cited as background context in every major CUX2 and DEE67 paper that followed.
Range of Genetic Mutations Associated with Severe Non-Syndromic Sporadic Intellectual Disability: An Exome Sequencing Study
Publication Date: September 27, 2012
Primary Researchers: Anita Rauch, Dagmar Wieczorek, Elisabeth Graf, Thomas Wieland, Sabine Endele, Thomas Schwarzmayr, Tim M. Strom, and colleagues from institutions across Germany and Switzerland (The Lancet)
AI Summary: This paper is generally recognized as the first published study to identify a CUX2 mutation in a human patient with a neurodevelopmental condition. Using a relatively new genetic testing method called exome sequencing, researchers examined the DNA of 51 children with severe intellectual disability and no family history of the condition, alongside both of their parents. The purpose was to find spontaneous mutations that might explain why these children had intellectual disability when no inherited cause could be found. A CUX2 mutation was identified in one patient, making this the earliest scientific documentation connecting a broken CUX2 gene to a serious developmental condition in a human being.
This paper was groundbreaking not because of what it said about CUX2 specifically, but because it demonstrated the power of a new type of genetic testing to find answers in children who had previously been undiagnosed. It established the scientific precedent and technical method that all subsequent CUX2 and DEE67 research built upon. For families, this paper represents the earliest moment in the scientific timeline when a broken CUX2 gene was recognized as something that could cause serious harm to a child's development, six years before DEE67 was formally named.
URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61480-9/abstract
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.